Publications

The Fusion Energy Sciences office supported “A Pilot Program for Research Traineeships to Broaden and Diversify Fusion Energy Sciences” at Sandia National Laboratories during the summer of 2021. This pilot project was motivated in part by the Fusion Energy Sciences Advisory Committee report observation that “The multidisciplinary workforce needed for fusion energy and plasma science requires that the community commit to the creation and maintenance of a healthy climate of diversity, equity, and inclusion, which will benefit the community as a whole and the mission of FES”. The pilot project was designed to work with North Carolina A&T (NCAT) University and leverage SNL efforts in FES to engage underrepresented students in developing and accessing advanced material solutions for plasma facing components in fusion systems. The intent was to create an environment conducive to the development of a sense of belonging amongst participants, foster a strong sense of physics identity among the participants, and provide financial support to enable students to advance academically while earning money. The purpose of this assessment is to review what worked well and lessons that can be learned. We reviewed implementation and execution of the pilot, describe successes and areas for improvement and propose a no-cost extension of the pilot project to apply these lessons and continue engagement activities in the summer of 2022.

Genome editing technologies, particularly those based on zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR (clustered regularly interspaced short palindromic repeat DNA sequences)/Cas9 are rapidly progressing into clinical trials. Most clinical use of CRISPR to date has focused on ex vivo gene editing of cells followed by their re-introduction back into the patient. The ex vivo editing approach is highly effective for many disease states, including cancers and sickle cell disease, but ideally genome editing would also be applied to diseases which require cell modification in vivo. However, in vivo use of CRISPR technologies can be confounded by problems such as off-target editing, inefficient or off-target delivery, and stimulation of counterproductive immune responses. Current research addressing these issues may provide new opportunities for use of CRISPR in the clinical space. In this review, we examine the current status and scientific basis of clinical trials featuring ZFNs, TALENs, and CRISPR-based genome editing, the known limitations of CRISPR use in humans, and the rapidly developing CRISPR engineering space that should lay the groundwork for further translation to clinical application.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Gene therapy has long held promise to correct a variety of human diseases and defects. Discovery of the Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR), the mechanism of the CRISPRbased prokaryotic adaptive immune system (CRISPR-associated system, Cas), and its repurposing into a potent gene editing tool has revolutionized the field of molecular biology and generated excitement for new and improved gene therapies. Additionally, the simplicity and flexibility of the CRISPR/Cas9 site-specific nuclease system has led to its widespread use in many biological research areas including development of model cell lines, discovering mechanisms of disease, identifying disease targets, development of transgene animals and plants, and transcriptional modulation. In this review, we present the brief history and basic mechanisms of the CRISPR/Cas9 system and its predecessors (ZFNs and TALENs), lessons learned from past human gene therapy efforts, and recent modifications of CRISPR/ Cas9 to provide functions beyond gene editing. We introduce several factors that influence CRISPR/ Cas9 efficacy which must be addressed before effective in vivo human gene therapy can be realized. The focus then turns to the most difficult barrier to potential in vivo use of CRISPR/Cas9, delivery. We detail the various cargos and delivery vehicles reported for CRISPR/Cas9, including physical delivery methods (e.g. microinjection; electroporation), viral delivery methods (e.g. adeno-associated virus (AAV); full-sized adenovirus and lentivirus), and non-viral delivery methods (e.g. liposomes; polyplexes; gold particles), and discuss their relative merits. We also examine several technologies that, while not currently reported for CRISPR/Cas9 delivery, appear to have promise in this field. The therapeutic potential of CRISPR/Cas9 is vast and will only increase as the technology and its delivery improves.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.